Sarepta’s RNA-targeted technology platforms (PMO and PPMO)
Dr. Gilmore O’Neill, Chief Medical Officer of Sarepta Therapeutics, Inc, gave a scientific overview of Sarepta’s RNA-targeted exon skipping technologies, PMO and PPMO. Dr. O’Neill provided valuable information on this groundbreaking science. If you were unable to participate, please use the link below to view the recording.
Click here to watch the recording of the webinar. You’ll be prompted to enter your name and email address to view the recording.